Standout Papers

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy... 2000 2026 2008 2017 509
  1. Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment (2000)
    Thomas A. Davis, Antonio J Grillo-López et al. Journal of Clinical Oncology

Immediate Impact

3 by Nobel laureates 11 from Science/Nature 60 standout
Sub-graph 1 of 22

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
STING-induced regulatory B cells compromise NK function in cancer immunity
2022 StandoutNature
2 intermediate papers

Works of Robin Weaver being referenced

Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up
2004
Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment
2000 Standout

Author Peers

Author Last Decade Papers Cites
Robin Weaver 786 532 447 5 1.1k
Elisabeth Wassner-Fritsch 1120 732 752 20 1.3k
W. Hiddemann 860 623 423 2 956
B. Christian 938 603 356 8 1.2k
P Solal-Céligny 1046 735 373 13 1.3k
J Sklar 524 308 365 13 930
Sophie Lefort 966 686 340 10 1.2k
Judith Estes 880 455 196 10 1.4k
Daming Shan 392 359 237 9 965
V. T. DeVita 506 449 182 7 1.1k
TC Meeker 435 401 348 16 1.1k

All Works

Loading papers...

Rankless by CCL
2026